OneDrug’s Post

🚀 Exciting News Alert! 🚀 Beckley Psytech reports positive initial findings from their Phase IIa clinical study (NCT05660642) of BPL-003 (5-MeO-DMT) for Treatment Resistant Depression (TRD). BPL-003 is benzoate salt formulation of 5-MeO-DMT (Mebufotenin), administered intranasally. In this open-label study, a single 10mg dose of BPL-003 was well-tolerated and demonstrated rapid, durable efficacy in patients with TRD. Key highlights include: ·      Rapid antidepressant response observed in 55% of patients the day after dosing. ·      55% of patients in remission from depression at day 29 and 45% at day 85 post-dosing. “Acute effects were resolved and patients were deemed dischargeable within an average time of less than 2 hours. This signals the potential for a shorter treatment duration and reduced resource burden for healthcare systems compared to other psychedelic treatments currently in development.” #psychedelics #clinicaltrials #mentalhealth #treatmentresistentdepression

Pioneering Progress: Navigating the US Growth Hormone Deficiency Clinical Trials Market! 🌟 Get Info : https://shorturl.at/fU579 🔍 Explore the breadth and depth of clinical trials focused on GHD across the United States, encompassing various phases of research and development. 📈 Uncover the latest breakthroughs and discoveries emerging from these trials, from novel therapeutic interventions to advanced diagnostic tools. 💊 Discover how these trials are shaping the future of GHD treatment by exploring new treatment modalities, optimizing dosing regimens, and enhancing patient outcomes. 🌐 Navigate the regulatory landscape governing clinical research in the US, including FDA guidelines and ethical considerations. 💡 Embrace the potential for collaboration and partnership in driving forward GHD research, with a shared goal of improving the lives of patients and families affected by this condition. #ClinicalTrials #GrowthHormoneDeficiency #MedicalResearch #Innovation

Source: Bioanalysis A study evaluated the feasibility of using fingerprints to determine carbamazepine levels in epilepsy patients as a way to assess adherence to medication. Fingerprints were collected and analyzed using LC-MS/MS, and the results showed that the method was accurate and precise. There was a significant difference in carbamazepine concentrations in fingerprints between patients with low and medium/high adherence. This method could potentially be used to identify epilepsy patients with low adherence to carbamazepine treatment.

The FDA's potential approval of an Alzheimer’s drug has sparked interest, as advisers recently endorsed its ability to slow down the disease, despite concerns about side effects like brain swelling. The decision, expected later this year, could be a significant step forward in Alzheimer’s treatment for those with mild dementia. The drug’s effectiveness across different patient groups was a key consideration, although there are questions about whether screening for a specific brain protein is necessary before treatment. If approved, it would be among the few drugs targeting cognitive decline and memory issues in Alzheimer’s patients. #alzheimers #healthinnovation #aging #healthcare https://lnkd.in/gkfP34wU

https://lnkd.in/e7HF4EqW We are a MDA center of excellence, recognized for both muscle dystrophy and ALS. #als is cruel. There is no question. The very human desire for hope is real. These are very tough moral and medical conversations. In the end: the data has to tell the story. We are obliged to our patients to be inventive but also rigorous. #neuromuscular #drugdevelopment #medicine

"Although pharmacist-led interventions in anticoagulant (AC) therapy are widely accepted, there is a lack of evidence comparing their effectiveness with usual care in terms of AC therapy appropriateness and clinical outcomes. We aimed to estimate the comparative effectiveness of pharmacist-led interventions on the appropriateness and clinical outcomes of AC therapy". https://lnkd.in/dDFQktey

Metanlysis of 49 studies, 10 RCTs examined the relationship between RA and non-surgical Rx of periodontitis (NSRT) and in general short term studies show that NSPT benefits RA patients; and DMARD therapy benefits periodontitis

Modeling Finds FDA-Authorized Diabetes Digital Therapeutic Can be Cost-Effective

A network meta-analysis and meta-regression of intraclass comparison of inhaled corticosteroids for the risk of pneumonia in chronic obstructive pulmonary airway disorder. Class differences in pneumonia risk were observed in terms of pooled effect estimates but it is unlikely that any clinically relevant differences exist. Risk–benefit analysis supports inhaled corticosteroid use in moderate-severe COPD. Derek Stewart European Society of Clinical Pharmacy (ESCP) Yolande Hanssens Vibhu Paudyal Shusen Sun Filipa Alves da Costa Matej Štuhec PharmD PhD Univ.-Prof. Dr. Anita Weidmann Kannan Sridharan #pharmacy #pharmacists #pharmacylife #clinicalpharmacy #pharmaceuticalcare #pharmacycollege #pharmacystudents #pharmacytechnicians https://lnkd.in/dbMk5YAh

The Annals of Internal Medicine published a large scale GLP-1 study last week summarized below: • Increased Use for Obesity: Prescriptions for GLP-1 drugs like Ozempic have doubled among people with obesity, shifting away from their original purpose for treating type 2 diabetes. • Demographic Shift: Semaglutide is now predominantly prescribed to females, whites, and individuals with a BMI of 30 or more. • Drug Shortages: Rising demand for weight loss has caused shortages, impacting availability for diabetes patients. • Study Data: Analysis of 45 million Americans’ medical data from 2011-2023 highlighted this trend. • Public Health Impact: This shift shows increased recognition of GLP-1 drugs’ benefits for obesity but raises concerns about access for diabetes patients. The success of this class of medications validates the hormonal/biological underpinnings of obesity and concomitant diseases. We now know that diet and physical activity are critical but not the root cause of obesity. It starts with brain organization and the endocrine system. As more of these meds become available, progress will become widespread and the positive impact on health and healthcare systems could be stunning. Cost containment will be essential to ensure this treatment gets to all who need them, especially individuals of color who are disproportionately affected by obesity and diabetes. For more details, you can read the full article here.